House Bill Would Triple Medicare Drug Negotiations to 50 Drugs, Cap Out-of-Pocket Costs
Stalled
No legislative action in over 90 days.
How this policy affects specific groups of people
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
House Democrats introduced the Lowering Drug Costs for American Families Act to expand Medicare's negotiation power from 20 to 50 drugs annually and extend those prices to the commercial market, potentially reaching 164 million workers who receive coverage through employers.
The bill would increase the number of drugs Medicare negotiates and require the HHS Secretary to consider international prices from countries like Australia and the UK, addressing the fact that Americans pay significantly more for brand-name drugs than international counterparts.
Democratic leaders introduced legislation to build on the Inflation Reduction Act by allowing private health plans to access Medicare-negotiated prices and capping out-of-pocket costs for insulin at $35 per month for those with commercial insurance.
Document Type
Congressional Bill
Official Title
Lowering Drug Costs for American Families Act
Analysis generated by AI. Always verify with official sources.